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 Abstract :  Drug-metabolizing enzymes play a major role 
in the biotransformation and subsequent elimination of 
most drugs and xenobiotics from the body. Both phase I 
and phase II enzymes are highly polymorphic. Inter-indi-
vidual differences in genes coding for drug-metabolizing 
enzymes are important for understanding variability in 
drug response and for individualization of drug prescrip-
tion. The prevalence of genetic polymorphisms in drug 
metabolism varies widely with ethnicity, and marked differ-
ences in the distribution of allelic variants of genes encod-
ing drug-metabolizing enzymes have been documented in 
populations of different racial origin. This review aimed 
to summarize the available studies on genetic polymor-
phisms associated with drug metabolism conducted in 
Italian populations and to compare the frequency of the 
various metabolizer phenotypes and most common vari-
ant alleles (and resulting genotypes) with corresponding 
values from other populations. Notably, published data 
are not extensive, and most studies were performed on 
relatively low numbers of individuals. In general, the fre-
quency of polymorphisms in the cytochrome P450 ( CYP ) 
genes as well as in the investigated phase II enzymes in 
the Italian population was similar to values reported for 
other Caucasian populations. However, the prevalence of 
 CYP2D6 gene duplication among Italians was found to be 
very high, confirming the higher frequency of  CYP2D6 ult-
rarapid metabolizers in the Mediterranean area compared 
to Northern Europe. It is worth noting that a geographic 
gradient in the flavin-containing monooxygenase 3 poly-
morphism distribution was also seen, the Italian popu-
lation showing higher similarity to other Mediterranean 
populations than to North Europeans. 
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 Introduction 
 Pharmacogenetics is the study of the genetic basis leading 
to individual variation in drug response. It is well known 
that therapeutic failure and severe adverse drug reactions 
can both be influenced by an individual genetic make-up 
 [1] . The therapeutic outcome may be affected by genetic 
variation in genes coding for drug-metabolizing enzymes, 
drug transporters, drug targets, and biomarker genes  [2] . 
Identification of these gene variants has become one of 
the main goals of modern drug therapy and is frequently 
described as  “ personalized medicine ” . 
 Metabolic processes are necessary to convert a lipo-
philic drug into one or more metabolites which are more 
water soluble, thus facilitating urinary excretion. The bio-
chemical reactions involved in the biotransformation of 
drugs are catalyzed by various enzyme systems and are 
conventionally divided into phase I (functionalization) 
and phase II (conjugation) reactions, which may occur in 
series  [3] . Phase I reactions involve the addition of a polar 
functional group (e.g., a hydroxyl group) or the deletion 
of a non-polar alkyl group (e.g.,  N -demethylation) by oxi-
dation, reduction, or hydrolysis. In phase II reactions, the 
drug or the phase I metabolite is covalently attached to 
a water-soluble endogenous substrate (e.g., glucuronic 
acid, acetate, sulfate, glutathione, or glycine), usually 
resulting in an inactive, easily excretable compound. 
 Genetically determined variability in the activity 
of these enzymes may result in inter-individual dif-
ferences in the pharmacokinetics and plasma/serum 
concentrations of a given drug. As most therapeutic 
agents undergo extensive hepatic biotransformation, 
differences in treatment outcome may be attributed to 
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predictable variations in genes encoding drug-metabo-
lizing enzymes. Over the past few decades, advances in 
pharmacogenetic research have led to the discovery of 
several polymorphisms associated with drug metabo-
lism. A genetic polymorphism is defined as a stable vari-
ation in a given locus of the genetic sequence, which 
is detected in 1% or more of a specific population  [1] . 
These polymorphisms reflect gene insertions and dele-
tions, gene duplications, copy number variations, and 
single nucleotide polymorphisms (SNPs), and can lead 
to enzyme variants with higher, lower, or no activity, 
or occasionally the total absence of the enzyme. The 
resulting phenotypes associated with these genetic vari-
ants are usually classified into four groups: poor (PMs), 
intermediate (IMs), extensive (EMs), and ultrarapid 
metabolizers (UMs)  [2] . Phenotyping and/or genotyp-
ing procedures may therefore allow the identification of 
patients at risk of inefficacy or toxicity and offer tools to 
individualize drug prescription  [4] . 
 Inter-ethnic differences in drug metabolism are well 
documented for a number of medications  [5] . Racial/
ethnic differences in drug metabolism may be explained 
by differences in the distribution of allelic variants of 
genes encoding drug-metabolizing enzymes in differ-
ent ethnic groups. Ethnic diversity in drug response may 
represent an important regulatory aspect that should be 
considered during drug development if data on recom-
mended doses of a drug are to be extrapolated from one 
ethnic group to another  [6] . 
 Given the importance of inter-ethnic pharmacoge-
netic differences in drug safety and efficacy, the aim of this 
review was to summarize the available studies on genetic 
polymorphisms associated with drug-metabolizing 
enzymes conducted in Italian populations and to compare 
the frequency of the various metabolizer phenotypes and 
most common variant alleles (and resulting genotypes) 
with corresponding values from other populations. 
 Pharmacogenetics of phase 
I enzymes: studies in Italian 
populations 
 The cytochrome P450 (CYP) system represents the major 
enzyme family responsible for the phase I oxidative reac-
tions. Other phase I drug-metabolizing enzymes include 
the flavin-containing monooxygenase, alcohol dehydro-
genase, monoamine oxidase, epoxide hydrolase, and 
esterase systems. 
 Cytochrome P450 enzymes 
 CYPs are members of a superfamily of monooxygenases 
that catalyze the oxidative biotransformation of many 
drugs, nutrients, environmental toxins, and endogenous 
substances (i.e., steroid hormones, prostaglandins, bile 
acids, fatty acids)  [2, 7] . These enzymes, located in the 
membranes of the smooth endoplasmic reticulum as well 
as in the mitochondria in the liver and in many extrahe-
patic tissues, are classified into families and subfamilies 
according to similarities in their amino acid sequence 
 [8] . The enzymes found in mitochondria are generally 
involved in the synthesis and metabolism of internal sub-
stances, while enzymes in the endoplasmic reticulum 
usually metabolize external substances, primarily medica-
tions and environmental pollutants. The human genome 
comprises 57 CYP genes which are grouped according to 
sequence homology into 18 families and 44 subfamilies. 
Only about a dozen enzymes belonging to the 1, 2, and 
3 CYP families are involved in phase I drug metabolism 
 [2, 8] . CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and 
CYP3A4/5 are the CYP isoforms which play a major role in 
the biotransformation of therapeutic agents  [2, 7] . Other 
clinically relevant isoforms include CYP1A1, CYP2A6, 
CYP2C8, and CYP2E1. Each CYP isoform is a specific gene 
product and possesses a characteristic but relatively broad 
spectrum of substrate specificity. Genetic polymorphisms 
have been discovered in virtually all CYP enzymes. The 
most important polymorphic enzymes in relation to their 
clinical implications are CYP2C9, CYP2C19, and CYP2D6. 
 CYP2C9, CYP2C19, and CYP2D6 
 CYP2C9 accounts for approximately 20% of the hepatic 
total CYP content  [9] and is responsible for the metabolism 
of a variety of therapeutic agents including non-steroidal 
anti-inflammatory drugs, oral antidiabetics, diuretics, 
angiotensin II receptor antagonists, anticancer drugs, oral 
anticoagulants (e.g., S-warfarin), and antiepileptics (e.g., 
phenobarbital and phenytoin)  [10 – 12] . The  CYP2C9 gene 
is located at chromosome 10q24 in a multigene cluster 
containing the other  CYP2C subfamily members ( CYP2C8 , 
 CYP2C18 , and  CYP2C19 ).  CYP2C9 exhibits genetic poly-
morphisms and, to date, more than 35 allelic variants 
have been described, according to the Human Cytochrome 
P450 (CYP) Allele Nomenclature Database ( http://www.
cypalleles.ki.se ). The two more common variants associ-
ated with the reduced enzyme activity are  CYP2C9∗2 and 
 CYP2C9∗3 ( Table 1 ). There are significant inter-ethnic 
differences in the frequency of these two variants  [2] . 
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 Table 1   Overview of the most common and functionally relevant CYP allelic variants and their impact on metabolic activity 
( http://www.cypalleles.ki.se ). 
Gene   Allele (SNP ID)   Consequences on gene structure   Impact on enzyme activity 
 CYP2C9    CYP2C9∗2 (rs1799853)   Reduced oxidoreductase affinity   Reduced activity
   CYP2C9∗3 (rs1057910)   Reduced substrate affinity   Reduced activity
 CYP2C19    CYP2C19∗2 (rs4244285)   Splicing defect   Lack of activity
   CYP2C19∗3 (rs4986893)   Premature stop codon   Lack of activity
   CYP2C19∗17 (rs12248560)  Increased transcription   Enhanced activity
 CYP2D6    CYP2D6∗3 (rs35742686)   Frameshift   Lack of activity
   CYP2D6∗4 (rs3892097)   Splicing defect   Lack of activity
   CYP2D6∗5   Gene deletion   Lack of activity
   CYP2D6∗6 (rs5030655)   Frameshift   Lack of activity
   CYP2D6∗41 (rs28371725)   Splicing defect   Reduced activity
   CYP2D6∗2xn   Gene duplication   Enhanced activity
 CYP3A4    CYP3A4∗1B (rs2740574)   Altered 5 ′ regulatory element   Reduced activity
   CYP3A4∗3 (rs4986910)   Amino acid change (M445T)   Reduced activity
   CYP3A4∗4 (rs55951658)   Amino acid change (I118V)   Reduced activity
 CYP3A5    CYP3A5∗2 (rs28365083)   Amino acid change (T398N)   Lack of activity
   CYP3A5∗3 (rs776746)   Splicing defect   Lack of activity
   CYP3A5∗6 (rs10264272)   Splicing defect   Lack of activity
 CYP1A1    CYP1A1∗2C (rs1048943)   Amino acid change (I462V)   Enhanced activity
 CYP2E1    CYP2E1∗5 (rs2031920)      Reduced activity 
 CYP2C9∗2 and  CYP2C9∗3 are mainly present in Cauca-
sians at a frequency of 11% and 7%, respectively, while 
frequencies are lower in Africans.  CYP2C9∗2 has indeed 
not been detected in Asians [2]. 
 CYP2C19 is involved in the oxidative biotransformation 
of many commonly used medications including proton 
pump inhibitors, clopidogrel, some benzodiazepines (i.e., 
diazepam and clobazam), and antidepressants (i.e., ami-
triptyline, imipramine, citalopram, and escitalopram) 
 [2, 10, 12] . The  CYP2C19 gene is located on chromosome 
10q24.1 – q24.3. The  CYP2C19 gene is highly polymorphic; 
at least 35 allelic variants and subvariants  (∗1B to  ∗34 ) 
have been identified  [13] .  CYP2C19∗1 , the wild-type allele 
encoding a fully functional enzyme, is present in double or 
single copy in EMs (homozygotes or heterozygotes, respec-
tively). CYP2C19 PMs are carriers of null alleles  CYP2C19∗2 
and  CYP2C19∗3 (Table 1). About 2% – 5% of Caucasian and 
Afro-Caribbean populations but up to about 25% of Asians 
are CYP2C19 PMs There is a marked inter-ethnic variation 
in the distribution of these two variant alleles  [13, 14] . 
The allelic frequency of  CYP2C19∗2 has been shown to be 
15% in Africans, 29% – 35% in Asians, 12% – 15% in Cauca-
sians, and 61% in Oceanian peoples.  CYP2C19∗3 is mainly 
found in Asians (5% – 9% in Asians,  < 0.5% in Caucasians). 
A  CYP2C19 gene variant ( CYP2C19 ∗ 17 ), associated with 
increased gene transcription and thus a higher metabo-
lism of CYP2C19 substrates, has been described  [15] . Its 
frequency varies quite broadly between different ethnic 
groups, being 18% among Swedes and 4% in Chinese  [15] . 
 CYP2D6 is the most important polymorphic enzyme 
involved in drug metabolism. Although it represents  < 5% 
of the hepatic total CYP content  [9] , CYP2D6 plays an 
important role in drug metabolism, being partially or 
entirely responsible for the biotransformation of several 
commonly prescribed drugs such as antidepressants, 
antipsychotics, opioids, antiemetics, antiarrhythmics, 
beta-blockers, and anticancer drugs  [12, 16, 17] . The gene 
encoding CYP2D6 is located in position 22q13.1 and is 
highly polymorphic. Currently more than 100 allelic vari-
ants and subvariants have been identified, with substan-
tial ethnic differences in allele frequencies  [7, 16] . Some 
variants encode an inactive enzyme or no enzyme at all, 
while others are characterized by gene duplication and 
lead to increased activity. These gene variants are asso-
ciated with various drug metabolism rates  – individuals 
being classified as PMs, IMs, EMs, or UMs according to their 
inherited genetic profile. PMs lack CYP2D6 activity and 
represent approximately 3% – 10% of Caucasians, but only 
1% – 2% of East Asians. Among EMs, the catalytic activity 
varies largely, and a subgroup of subjects with extremely 
high enzyme activity has been classified as UMs. Four 
major mutated alleles,  CYP2D6∗3 ,  CYP2D6∗4 ,  CYP2D6∗5 , 
and  CYP2D6∗6 , account for 90% – 95% of the PM alleles in 
Caucasians, while the  CYP2D6∗41 allelic variant, which 
causes an impaired CYP2D6 expression, is the main factor 
underlying the IM phenotype (Table 1). Alleles with dupli-
cation or multiduplication of a functional  CYP2D6∗2 gene 
are associated with increased CYP2D6 activity. The overall 
Authenticated | espina@unime.it author's copy
Download Date | 1/10/15 12:07 PM
4      Serpe et al.: Pharmacogenetics of drug-metabolizing enzymes in Italian populations
frequency of the gene duplications is between 1% and 
5% in Caucasians with values up to 7% – 10% in Spanish 
and Southern Italian populations [10]. The incidence of 
this gene duplication can reach 10% and even up to 50% 
in some Arab, Eastern African, and Pacific populations. 
A comprehensive worldwide study provided CYP2D6 UM 
frequencies of 1% – 5% in Caucasians, 40% in northern 
Africa, and  > 20% in Oceania  [18] . 
 Over the past two decades, a limited number of phar-
macogenetic studies have evaluated the prevalence of 
these three CYP polymorphisms in Italian populations. 
The first study on the CYP2D6-related oxidation polymor-
phism in an Italian population was performed by Spina 
et al.  [19] . In this study, the frequency of the CYP2D6 phe-
notypes was investigated in 246 healthy volunteers from a 
Southern Italian population using dextromethorphan as 
a metabolic marker. The urinary metabolic ratios of dex-
tromethorphan (parent drug) to dextrorphan (the oxidized 
metabolite of dextromethorphan) ranged from   ≤  0.001 to 
6.6. By applying a metabolic ratio of 0.30 as cut-off to dif-
ferentiate between PMs and EMs, 11 (4.5%) subjects could 
be classified as PMs, while the remaining 235 were classi-
fied as EMs. The frequency of the CYP2D6 PM phenotype 
in this population was within the range described for 
other Caucasian ethnic groups  [16] . 
 After a preliminary study describing the distribution 
of variant  CYP2C9 alleles in small samples of an Italian 
(n = 157 subjects) and an Ethiopian (n = 150) population 
 [20] , Scordo et  al.  [21] investigated the genotype profile 
of a sample of the Italian population in order to compare 
the  CYP2C9 ,  CYP2C19 , and  CYP2D6 allele frequencies 
among Italians with previous findings in other Caucasian 
populations. Frequencies for the major  CYP2C9 ,  CYP2C19 , 
and  CYP2D6 mutated alleles and genotypes were inves-
tigated in 360 unrelated healthy Italian volunteers (210 
males and 150 females, aged 19 – 52 years). Most sub-
jects were students or employees at the Medical School 
of the University of Messina, Sicily, Italy. The  CYP2C9 , 
 CYP2C19 , and  CYP2D6 allele as well as genotype frequen-
cies in the Italian population are summarized in  Tables 2 
and  3 , respectively. Concerning  CYP2C9 allelic variants, 
the frequency of  CYP2C9∗2 found in this study (0.125) 
was very similar to values reported in studies of differ-
ent Caucasian populations  [7] . In contrast, the  CYP2C9∗2 
allele frequency was nil in various Oriental populations 
and very low in African Americans  [7] . The frequency of 
 CYP2C9∗3 in this group of Italian volunteers (0.097) was 
very similar to the frequencies found in other Caucasian 
populations, and higher than those among African Amer-
icans and Orientals  [7] . As shown in Table 3, 23 subjects 
(6.4%) carried two detrimental  CYP2C9 alleles, while 114 
(31.7%) carried one detrimental allele. The frequency of 
the allelic variant  CYP2C19∗2 observed in this population 
(0.111) was consistent with findings in other Caucasian 
populations  [7] . Six individuals (1.7%) were homozygous 
for  CYP2C19∗2 , and could therefore be classified as PM, 
 Table 2   Allele frequencies of  CYP2C9 ,  CYP2C19 , and  CYP2D6 in 360 healthy Italian volunteers  [21] and in other populations  [7] . 
Gene   Allelic variant   Allele frequency in an Italian 
population (95% confidence 
intervals) 
  Allele frequencies in other populations 
 CYP2C9    CYP2C9∗2   0.125 (0.101 – 0.149)  0 – 0.02 (African American, African, Asian, Pacific)
   CYP2C9∗3   0.097 (0.075 – 0.119)  0.10 – 0.17 (Caucasian)
      0.065 (Hispanic)
      0 – 0.01 (African American, African)
      0.02 – 0.06 (Asian)
      0.06 (Caucasian)
 CYP2C19    CYP2C19∗2   0.111 (0.088 – 0.134)  0.10 – 0.17 (African American, African)
   CYP2C19∗3   0  0.22 – 0.32 (Asian, Pacific)
      0.06 – 0.15 (Caucasian)
      0.15 (Hispanic)
      0 – 0.01 (African, Caucasian, Hispanic)
      0.03 – 0.07 (Asian, Pacific)
 CYP2D6    CYP2D6∗3   0.007 (0.001 – 0.013)  Approx. 0.01 (all ethnicities)
   CYP2D6∗4   0.153 (0.127 – 0.179)  0.1 – 0.10 (African American, African, Asian, Hispanic)
   CYP2D6∗5   0.034 (0.021 – 0.047)  0.15 – 0.25 (Caucasian)
   CYP2D6∗6   0.014 (0.005 – 0.023)  0.03 – 0.06 (All ethnicities)
   CYP2D6∗2x2   0.042 (0.027 – 0.047)  Approx. 0.01 (All ethnicities)
      Up to 0.30 (African, Arab)
         0.01 – 0.09 (Caucasian) 
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 Table 3   Genotype frequencies of  CYP2C9 ,  CYP2C19 , and  CYP2D6 in 
360 healthy Italian volunteers  [21] . 
Gene   Genotype   No. of subjects   Frequency 
 CYP2C9    CYP2C9∗1/∗1   223   61.9
   CYP2C9∗1/∗2   62   17.2
   CYP2C9∗1/∗3   52   14.5
   CYP2C9∗2/∗2   10   2.8
   CYP2C9∗2/∗3   8   2.2
   CYP2C9∗3/∗3   5   1.4
 CYP2C19    CYP2C19∗1/∗1   286   79.4
   CYP2C19∗1/∗2   68   18.9
   CYP2C19∗2/∗2   6   1.7
 CYP2D6    CYP2D6∗1/∗1   192   53.3
   CYP2D6∗1/∗3 (∗4, ∗5, ∗6)   126   35.0
   CYP2D6∗3/∗4, ∗4/∗4, ∗4/∗5   12   3.4
    CYP2D6∗1/∗2×2   30   8.3 
while 68 subjects (18.9%) were carrying one mutated 
allele ( CYP2C19∗1/∗2 ). On the other hand, the variant 
 CYP2C19∗3 was not detected among the Italian volunteers. 
This further illustrates the ethnic difference between 
Caucasian and Oriental populations, by confirming the 
Asian specificity of this allelic variant, the frequency of 
which is very low, or totally absent, in different Cauca-
sian populations  [7] . The frequency of the most common 
 CYP2D6 mutated alleles was similar to that described in 
other Caucasian populations  [7] . As reported in Table 
3, 12 subjects carried two  CYP2D6 detrimental alleles 
( CYP2D6∗3/∗4 , n = 1;  CYP2D6∗4/∗4 , n = 2;  CYP2D6∗4/∗5 , 
n = 9), and could thus be classified as PM with respect to 
CYP2D6. Among the rest, 126 subjects carried one detri-
mental allele ( CYP2D6∗1/∗3 , n = 4;  CYP2D6∗1/∗4 , n = 96; 
 CYP2D6∗1/∗5 , n = 16;  CYP2D6∗1/∗6 , n = 10), while in the 
remaining 222 volunteers, no defect alleles were identi-
fied. Of the 360 volunteers, 30 (8.3%) were found to carry 
a duplicated functional  CYP2D6 gene and were thus clas-
sified as UM. The results indicate that the prevalence of 
this allelic variant in the Southern Italian (Sicilian) popu-
lation is similar to that in a Spanish population  [22, 23] . 
This is consistent with the more frequent distribution 
of  CYP2D6 gene duplication in the Mediterranean area 
compared to Northern Europe and may be indicative of a 
north-south gradient of the frequency within Europe. The 
highest incidence of gene duplication has been found in 
Ethiopia in Northern Africa at 29%  [24] . 
 The preliminary findings of a study we have conducted 
in 150 Italian patients in therapy with warfarin to evaluate 
the impact of several genetic factors on the therapeutic 
outcome showed a 17% frequency of the  CYP2C19∗17 allele 
( data not published ), which is in line with the frequencies 
seen in other Caucasian populations. 
 A recent study investigated the frequency of well-
known polymorphic variants of some CYPs, namely 
CYP2C9, CYP2C19, and CYP2D6, in different environmental 
sensitivity-related illnesses including multiple chemical 
sensitivity, chronic fatigue syndrome, and fibromyalgia 
 [25] . Allele and genotype distribution for different  CYP2C9 , 
 CYP2C19 , and  CYP2D6 variants in 113 healthy controls did 
not differ substantially from previously reported frequen-
cies in the Italian general population  [21] . 
 Other CYP polymorphisms: CYP1A1, CYP2E1, 
and CYP3A4/3A5 
 Other polymorphisms in the CYP family studied in Italian 
populations include those related to the  CYP1A1 ,  CYP2E1 , 
and  CYP3A4/3A5 genes. 
 CYP1A1 is an aryl hydrocarbon hydroxylase which 
catalyzes the first step in the metabolism of polycyclic 
aromatic hydrocarbons such as those found in cigarette 
smoke, transforming them into active carcinogens. The 
non-synonymous m2 variant ( CYP1A1∗2C , 2454A > G, Ile-
462Val) of the  CYP1A1 gene has been associated with an 
increased enzymatic activity  [26, 27] and with an increased 
risk of bronchial, laryngeal, and oral cavity tumors among 
smokers  [26] . This variant has a frequency of about 10% in 
the Caucasian population, but it is more common among 
Asian and Spanish populations  [7] . 
 CYP2E1 is a key enzyme in the metabolic activation 
of a variety of toxicants including nitrosamines, benzene, 
vinyl chloride, and halogenated solvents such as trichlo-
roethylene  [28] . This enzyme is also believed to participate 
in the oxidation of other compounds, such as ethanol, to 
produce reactive free radicals that may initiate lipid per-
oxidation and also contribute to carcinogenesis  [28] . The 
variant c2 allele, recognized by  Rsa I digestion in the 
5 ′ -flanking region of the gene, appears to be associated 
with decreased enzyme activity. The presence of this allele 
has been related to cancer susceptibility and its frequency 
is variable, but relatively low in different populations, 
being around 5% in Caucasians  [28] . 
 Bianchino et  al.  [29] performed a case-control study 
to evaluate the distribution of the major polymorphisms 
in the  CYP1A1 and  CYP2E1 genes in a Southern Italian 
population and their association with cancer susceptibil-
ity. The enrolled participants were resident of Basilicata 
and included 290 cancer patients (mean age of 65 years: 
range 34 – 78 years) as cases and 242 healthy individuals 
(mean age of 64 years: range 50 – 78 years) admitted to the 
hospital for routine blood tests and who had no personal 
and/or family history of cancer (controls). The  CYP1A1 
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heterozygous genotype was found in 14 (5%) of the cancer 
patients and in 18 (7.4%) of the controls, while the  CYP2E1 
heterozygous genotype was found in 12 (4%) of the cancer 
patients and in 20 (8.3%) of the controls. No mutant 
homozygotes were identified for either of the genes in the 
cases or in the controls. The distribution of the studied 
polymorphisms did not differ from those reported for 
other Caucasian populations. 
 The human CYP3A subfamily is composed of three 
isoforms, 3A4, 3A5, and 3A7, with overlapping substrate 
specificity, encoded by genes located on chromosome 
7. These enzymes play a major pharmacokinetic role, 
catalyzing, at least partially, the biotransformation of 
a large number of structurally diverse drugs, as well as 
endogenous compounds. CYP3A4 is the most abundant 
isoform in the human liver, accounting for approxi-
mately 30% of the total CYP liver content, and for the 
majority of CYPs in the human small bowel  [9] . CYP3A4 
drug-metabolizing activity has been reported to vary 
more than 20-fold among individuals. Three  CYP3A4 
variants ( CYP3A4∗1B ,  CYP3A4∗3 , and  CYP3A4∗4 ) 
(Table  1) have been reported to cause a reduction in 
enzyme activity and to affect the  in vivo biotransforma-
tion of some commonly used drugs including simvas-
tatin and the immunosuppressants cyclosporine and 
tacrolimus  [30] . On the other hand, only subjects car-
rying at least one  CYP3A5∗1 allele (about 10% of the 
population) express the CYP3A5 enzyme. The absence 
of CYP3A5 among a majority of Caucasians is largely 
dependent on the  CYP3A5∗3 allele  [31] .  CYP3A5∗6 and 
 CYP3A5∗2 are more rare variants coding for a non-func-
tional protein  [31] (Table 1). 
 Magliulo et al.  [32] have evaluated the distribution 
of  CYP3A43A/5 polymorphisms in an Italian popula-
tion, and their impact on Alzheimer (AD) treatment 
with donepezil, in 54 AD patients and 285 Italian vol-
unteers. Three AD patients (5.6%) and 24 (8.4%) vol-
unteers carried one detrimental  CYP3A4 allele [AD 
patients:  CYP3A4∗1/∗1B (n = 2) and  CYP3A4∗1/∗3 (n = 1); 
volunteers:  CYP3A4∗1/∗1B (n = 20) and  CYP3A4∗1/∗3 
(n = 4)]. Twelve AD patients (22.2%) were heterozygous 
for  CYP3A5∗1 , while all the others (77.8%) were homozy-
gous for the  CYP3A5∗3 allele. Among the volunteers, 246 
(86.3%) were homozygous for  CYP3A5∗3 and 4 (1.4%) 
carried the  CYP3A5∗3/∗6 genotype. Five volunteers 
(1.7%) were homozygous and 30 (10.5%) were heterozy-
gous for  CYP3A5∗1 . No AD patient or volunteer carried 
 CYP3A4∗4 or  CYP3A5∗2 alleles. The frequencies of the 
allelic variants of CYP3A4 and CYP3A5 did not differ 
between patients and volunteers and were similar to 
those reported in other Caucasian populations  [32] . 
 Flavin-containing monooxygenases 
(EC 1.14.13.8) 
 Flavin-containing monooxygenases (FMOs) are a family 
of microsomal flavin adenine dinucleotide (FAD-), nico-
tinamide adenine dinucleotide phosphate (NADPH-), or 
O 2 -dependent flavoprotein enzymes that catalyze the oxy-
genation of several nucleophilic heteroatom-containing 
chemicals, such as those having nitrogen, sulfur, phos-
phorous, and selenium as their site of oxygenation  [33, 
34] . FMO3 is the predominant form of the FMO family 
expressed in the adult human liver involved in the metabo-
lism of xenobiotics. Substrates for FMO3 include dietary-
derived tyramine, trimethylamine, and nicotine and some 
therapeutic agents such as the H 2 -receptor antagonists 
cimetidine and ranitidine, the non-steroidal anti-inflam-
matory agents benzydamine and sulindac, the anties-
trogen tamoxifen, and the antipsychotics clozapine and 
olanzapine  [33] . E158K, V257M, and E308G are common 
 FMO3 polymorphisms with marked variability in frequency 
between major ethnicities, whereas D132H and L360P have 
only been identified in African Americans  [35] . 
 Mao et al.  [36] investigated the frequency of these  FMO3 
polymorphisms in 2152 healthy volunteers from 13 defined 
groups representing Caucasians, Japanese, and Africans. 
The Italian population consisted of 279 subjects. Significant 
subpopulation differences in allele frequencies were found 
for E158K, V257M, and E308G in Caucasians and regional 
differences for D132H among Africans. No carriers of  P360 
were identified. Concerning the three most widespread pol-
ymorphisms, the  K158 variant was the commonest variant 
allele in all populations. Among Caucasians, this allele 
was more frequent in Swedes (44.3%) than in either Italian 
(33.5%) or Turkish groups (35.8%), while among Africans 
its frequency ranged from 33.3% to 52.0%. The Japanese 
had a lower frequency (22.7%) as compared to Caucasians 
and Africans. The frequency of the  G308 allele also varied 
between different populations. The frequency among Japa-
nese (21.9%) was similar to that in Swedes (22.4%), but it 
was lower in both the Italian (10.8%) and Turkish popula-
tion (6.0%), whilst it ranged from 0% to 1.6% in the various 
African groups. The frequency of the M257 variant was 
below 8% in Caucasians (6.3% in the Italian population) 
and Africans, but higher (14.5) in the Japanese group. 
 A recent study by D ’ Angelo et al.  [37] investigated the 
distribution of the three common  FMO3 polymorphisms 
in an Italian population of 528 healthy subjects: 290 
from Sicily and 238 from Sardinia. Variant  158K showed 
the same frequency of 30% in both Sicilian and Sardin-
ian populations, while variant  308G showed a slightly 
higher frequency in the Sardinian (20%) than in the 
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Sicilian sampling (10%). By contrast, the  257M allele was 
present in the Sicilian sample, with a frequency of 2%, but 
it was not observed in the Sardinian sample. The authors 
hypothesize that differences can be explained by the fact 
that the two islands, despite their proximity, differ consid-
erably in their ancient history  [37] . 
 Pharmacogenetics of phase II 
enzymes: studies in Italian 
populations 
 Phase II enzymes are involved in chemical reactions where 
substrates, drugs, or intermediates undergo biotransfor-
mation to generate products that are more hydrophilic 
than the parent compound, increasing their propensity 
to be readily excreted in urine and feces. They include a 
large number of enzyme families such as uridine diphos-
phate glucoronosyltransferases (UGTs),  N -acetayltrans-
ferases (NATs), thiopurine S-methyltranferase (TPMT), 
catechol O-methyltransferase (COMT), sulfotransferases 
(SULTs), and glutathione S-transferases (GSTs)  [38 – 40] . 
These enzymes also have an important role in preventing 
the formation of reactive intermediates and toxic metabo-
lites generated by phase I enzymes for products such as 
paracetamol, polycyclic aromatic hydrocarbons, and aro-
matic amines  [41] . The UGTs, NATs, SULTs, and GSTs con-
jugate these reactive species and, by rendering them more 
hydrophilic, minimize their toxicity and enhance their 
elimination. For this reason many studies have associated 
the presence of SNPs or allelic variants of phase II genes 
with the incidence of different diseases  [42, 43] . 
 Uridine diphosphate 
glucoronosyltransferases 
 The uridine diphosphate glucoronosyltransferases (UGTs) 
belong to a multigene family of important enzymes local-
ized on the internal membrane of the endoplasmic reticu-
lum and involved in the inactivation and the elimination 
of a wide range of nucleophilic substances, both endog-
enous and exogenous  [44] . The UGT superfamily is clas-
sified into the UGT1, UGT2, UGT3, and UGT8 families and 
is further divided into subfamilies and isoforms, based on 
similarities between their amino acid sequences and gene 
organization. To date, 117 mammalian genes have been 
identified and some of these as  UGT1A1 ,  1A3 ,  1A4 ,  1A6 , 
 1A7 ,  1A8 ,  1A10 ,  UGT2B4 ,  2B7 ,  2B15 , and  2B17 with impor-
tant implications in drug response. 
 UGT1A1 is active in the conjugation of numerous 
anticancer drugs including irinotecan, etoposide, and 
epirubicin  [44] . Irinotecan undergoes bioactivation by 
tissue carboxylesterases to produce the active cytotoxic 
metabolite SN-38 which is in turn glucuronidated by 
the polymorphic UGT1A1. Patient response to therapy 
is highly variable in part because defective alleles of 
UGT1A1 impair glucuronidation of SN-38 leading to its 
accumulation and resultant toxicity, including diar-
rhea and leucopenia  [45, 46] . Individuals who carry the 
variant  UGT1A1∗28 allele, which has a (TA) insertion 
in the  UGT1A1 promoter region, TA 7 repeats instead of 
more common TA 6 repeats, have a decreased capacity 
to glucuronidate SN-38  [47] . Up to 33% of Caucasians 
carry the  UGT1A1∗28 variant  [48] , and the US Food and 
Drug Administration has recommended a dose reduc-
tion for irinotecan in individuals who are homozygous 
for the  UGT1A1∗28 allele. Apart from irinotecan/SN-38, 
 UGT1A1∗28 is also associated with decreased paraceta-
mol, lamotrigine, lorazepam, and josamycin metabo-
lism, but the pharmacokinetic and pharmacodynamic 
consequences of variant alleles have not been evaluated 
to date  [47] . 
 The only study which investigated the frequency of 
 UGT1A1∗28 in an Italian population was carried out in 83 
healthy Italian pediatric subjects enrolled in a case-con-
trol study aimed at investigating the genetic susceptibility 
to Gilbert ’ s syndrome  [49] . Among 83 unaffected controls, 
9 (10.8%) were homozygous for the  UGT1A1∗28 allele and 
37 (44.6%) were heterozygous ( Table 4 ). Interestingly, the 
authors have also reported a rare UGT1A1 genotype (TA 7 /
TA 8 heterozygosity), confirming the low penetration of the 
TA 8 allele in Caucasian populations. 
 N -Acetyltransferases 
 N -Acetyltransferases (NATs) are cytosolic enzymes found 
in many tissues of various species. In humans, two forms 
are known, NAT1 and NAT2. Two functional human 
gene loci,  NAT1 and  NAT2 , were identified, described, 
and mapped to the short arm of human chromosome 8. 
The nucleotide sequences of these two genes show 85% 
homology and code two enzymes of different substrate 
specificity  [61] . Typical specific substrates for human 
NAT1 are  p -aminobenzoic acid,  p -aminosalicylic acid, and 
 p -aminobenzylglutamate  [62] . Human NAT2 provides a 
major route for detoxification of drugs such as isoniazid 
(antituberculotic drug), hydralazine (antihypertensive 
drug), procainamide (antiarrhythmic drug), and sulfona-
mides (antibacterial drugs)  [62] . 
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 Both  NAT genes exhibit more than 26 different alleles, 
and based on a  NAT genotype, individual phenotype (acet-
ylation activity) can be divided into slow, intermediate, 
and rapid acetylator  [38] . Acetylator status contributes to 
inter-individual variation in drug response with the slow 
acetylators more prone to dose-dependent toxicity  [39] . 
There is a general agreement that  NAT1∗4 should be con-
sidered the wild type (frequency in Caucasian approxi-
mately 75%)  [38] . The most frequent variant is  NAT1∗10 
(allele frequency in Caucasian approximately 20%)  [63] . 
It consists of a 1088T > A and a 1095C > A exchange in 
the 3 ′ -untranslated region. Other variants are  NAT1∗15 
(559C > T) with no enzyme activity, due to a premature stop 
in codon 187, and  NAT1∗14 (560G > A) with a low enzyme 
activity  [64] . 
 The common defective alleles of  NAT2 are 191G > A 
(Arg64Gln), 282C > T (Tyr94Tyr), 481C > T (Leu161Leu), 
341T > C (Ile114Thr), 590G > A (Arg197Gln), 803A > G 
(Arg268Lys), and 857G > A (Gly286Glu). These muta-
tions form haplotypes, the most important of which are 
 NAT2∗5B ,  NAT2∗6A ,  NAT2∗7B ,  NAT2∗12A , and  NAT2∗13. 
These haplotypes have provided the basis for a large 
 Table 4   Distribution of genes encoding phase II drug-metabolizing enzymes allele frequencies in Italian populations.  
Gene   No. of 
subjects 
  Genetic 
polymorphisms 
  Allele 
frequencies 
  Genotype/
phenotype 
  Genotype 
frequencies, % 
  Ref. 
 UGT1A1   83   ∗28   0.330   ∗1/∗1   44.6   [49] 
         ∗1/∗28   44.6 
         ∗28/∗28   10.8 
 NAT2   262   ∗5, ∗6, ∗7   n.d.  Slow acetylators   58.9   [50] 
     ∗4, ∗12, ∗13     Fast acetylators   41.1 
 NAT2   107   ∗5A, ∗6A, ∗7A   n.d.  Slow acetylators   51.8   [51] 
 TPMT   103   ∗3A   0.019   ∗1/∗1   95.5   [52] 
     ∗3C   0.005   ∗1/∗3A   3.9 
     ∗2   0.002   ∗1/∗3C   0.1 
         ∗1/∗2   0.5 
 TPMT   943   ∗3A   0.022   ∗1/∗1   94.6   [53] 
     ∗3B   0.003   ∗1/∗3A   4.3 
     ∗3C   0.003   ∗1/∗3B   0.5 
         ∗1/∗3C   0.5 
         ∗3B/∗3C   0.1 
 COMT   36  472G > A   0.444  Met/Met   22.3   [54] 
        Met/Val   44.5 
        Val/Val   33.2 
 COMT   57  472G > A   0.509  Met/Met   21.0   [55] 
        Met/Val   59.7 
        Val/Val   19.3 
 SULT   107   ∗2   0.220   ∗1/∗1   61.4   [51] 
         ∗1/∗2   33.5 
         ∗2/∗2   5.1 
 SULT   135   ∗2   0.280   ∗1/∗1   52.2   [56] 
         ∗1/∗2   40.4 
         ∗2/∗2   7.4 
 GSTM1   120   ∗O   n.d.  Null   49.2   [57] 
  546        50.4   [58] 
 GSTT1   120   ∗O   n.d.  Null   28.3   [57] 
  546        16.7   [58] 
 GSTP1   250   ∗A   0.710   ∗A/∗A   51.2   [59] 
     ∗B   0.240   ∗A/∗B   31.6 
     ∗C   0.050   ∗A/∗C   8.0 
         ∗B/∗B   6.4 
         ∗B/∗C   2.8 
 GSTP1   544  313A > G   0.550  Ile/Ile   23.5   [60] 
      0.450  Ile/Val   62.5 
            Val/Val   14.0    
 n.d., not determined; Ref., references. 
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number of genotyping studies on the ethnic distribution 
of  NAT2 polymorphisms  [65, 66] . Moreover, most  NAT2 
variants are in linkage disequilibrium; therefore, in order 
to predict the  NAT2 phenotype from the genotype, it is 
sufficient to genotype only three SNPs, i.e., SNPs 282C > T, 
341T > C, and 857G > A, for studies in a Caucasian or Orien-
tal population, whereas in Africans, 191G > A should also 
be considered  [38] .  NAT2 genotyping studies have revealed 
that the allelic pattern differs significantly between Cau-
casians, Asians, Aborigines, and Northern African popu-
lations  [38] . In Caucasians, the predominant alleles code 
for the slow  NAT2∗5B (40.9%) and  NAT2∗6A (28.4%) and 
the rapid  NAT2∗4 (23.4%) metabolizing enzymes  [38] . 
 To the best of our knowledge, genetic variations 
of  NAT1 were not described in an Italian population, 
whereas some common allelic mutations of  NAT2 includ-
ing  NAT2∗5 ,  NAT2∗6 , and  NAT2∗7 were studied by Boccia 
et al.  [51] and Betti et al.  [50] , who enrolled 254 and 262 
healthy volunteers, respectively. In these studies,  NAT2 
genotypes were investigated to find a potential associa-
tion between  NAT2 haplotypes, tobacco smoke, alcohol 
consumption, and risk of gastric cancer  [51] and between 
 NAT2 polymorphisms and malignant mesothelioma sus-
ceptibility  [50] . In the study by Boccia et  al.  [51] , slow 
acetylators, carrying  NAT2∗5A ,  NAT2∗6A , and  NAT2∗7A 
haplotypes, were present at a frequency of 51.8%, whereas 
in the study by Betti et  al.  [50] , slow acetylators, carry-
ing  NAT2∗5 ,  NAT2∗6 , and  NAT2∗7 polymorphisms, had a 
frequency of 58.9% (Table 4). Interestingly, both studies 
suggested a possible correlation between  NAT2 polymor-
phisms and susceptibility to malignant mesothelioma and 
gastric cancer even though larger prospective investiga-
tions are necessary to make this correlation stronger. 
 Thiopurine S-methyltranferase 
 One of the first examples of pharmacogenetic studies 
applied to drug therapy is the polymorphism of the gene 
thiopurine S-methyltransferase (TPMT) where more than 
20 TPMT SNPs have been identified and associated with 
a decreased level of TPMT enzyme activity inducing thi-
opurine drug (6-mercaptopurine, azathioprine, 6-thio-
guanine) toxicity  [67, 68] . Therefore, some authors have 
suggested that patients with low TPMT activity must be 
treated with thiopurine drugs at a 1/10 to a 1/15 of stand-
ard dose  [69] . 
 Several population studies have identified the pre-
dominant variant alleles.  TPMT∗3A (460 G > A and 719 
A > G) and  ∗3C (719 A > G) were identified as the predomi-
nant variant alleles, with  TPMT∗2 (238 G > A) contributing 
to a lesser extent. These three alleles account for over 95% 
of cases of inherited TPMT deficiency in Caucasian sub-
jects  [70] . 
 Rossi et al.  [52] investigated the genotype-phenotype 
correlation for TPMT in 103 unrelated healthy Italian sub-
jects. They found that besides the wild-type allele  TPMT∗1 
(94.6%),  TPMT∗3A was the most frequent allele (3.9%) 
and accounted for 72% of the mutant alleles detected in 
the Italian sample.  TPMT∗3C was the second most recur-
rent and its frequency approached at most 1%.  TPMT∗2 
occurred at a lower frequency (0.49%), whereas  TPMT∗3B 
was not detected at all (Table 4)  [52] . 
 Serpe et  al.  [53] evaluated the impact of genotype, 
age, and gender on the TPMT phenotype in a large-scale 
healthy Italian population. In 943 unrelated healthy 
Italian subjects aged 0.08 – 68  years (623 males and 320 
females), the genotype frequencies were  TPMT∗1 (94.5%), 
 ∗3A (4.3%),  ∗3B (0.5%), and  ∗3C (0.5%), whilst  ∗2 was 
not detected at all (Table 4)  [53] . These findings are in 
agreement with previous reports in Caucasian popula-
tions, confirming that the  ∗3A allele is the most common 
variant and also that  ∗3B allele is also present at a rather 
high frequency. The authors of the study  [53] explained 
this finding by the fact that they enrolled individuals from 
different areas of Italy as well as Sardinia, where the fre-
quency for  TPMT∗3B is relatively high  [71] . In conclusion, 
this study shows that genetic factors seem to be the major 
aspect in TPMT phenotype variability in adults, whereas 
in children other physiological factors should be taken 
into account when assessing the TPMT phenotype, such 
as age and gender. 
 Catechol O-methyltransferase 
 Catechol O-methyltransferase (COMT) is responsible for 
transfer of a methyl group from S-adenosylmethionine to 
catecholamines. COMT is presented in mammalian cells 
in two forms: in a cytoplasmic soluble form (S-COMT) 
and a membrane-bound form (MB-COMT) located in the 
cytosolic side of the rough endoplasmic reticulum  [72] . 
COMT substrates include not only neurotransmitters such 
as norepinephrine, epinephrine, and dopamine but also 
drugs having a catechol structure such as levodopa and 
methyldopa. 
 COMT inhibitors are drugs commonly used in the 
management of patients with Parkinson ’ s disease compli-
cated by motor fluctuations. Among them, entacapone is 
the most commonly used. Both substrates and inhibitors 
might be affected by  COMT gene variations, and the most 
well-studied polymorphism in  COMT has been linked to 
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the low enzyme activity of COMT. This polymorphism is 
due to a G-to-A transition at codon 158 (for MB-COMT) or 
codon 108 (for S-COMT) of the  COMT gene and results in 
the substitution of the amino acid valine (val) for methio-
nine (met) causing a 3- to 4-fold decrease in the activity 
level of the COMT enzyme  [73] . 
 The frequency of the low activity (Met158)  COMT allele 
was found to be 54% in Caucasians, 49% in Southwest 
Asians, and 32% in Kenyans  [74] . In a study aimed to eval-
uate the possible association between low enzyme activity 
 COMT alleles and borderline personality disorder, a high 
frequency (44.4%) of the low-activity allele was observed 
in a small sample of an Italian population consisting of 
36 healthy volunteers (Table 4)  [54] . Another study aimed 
to evaluate the relationship between Met158, the closely 
located rs4818 SNP, and hypnotizability confirmed a high 
frequency (50.9%) of the low enzyme activity  COMT allele 
in an Italian population (Table 4)  [55] . Although larger 
scale studies are lacking, the observed frequency of codon 
108/158 allele is consistent with findings in other Cauca-
sian populations  [74] . 
 Sulfotransferases 
 Sulfotransferases (SULTs) are a gene family of enzymes 
that catalyze the conjugation of 3 ′ -phosphoadenosine 
5 ′ -phosphosulfate with an O-, N-, or S-acceptor group of 
an appropriate molecule. Thus, they conjugate sulfate to 
many hormones, neurotransmitters, drugs, and xenobi-
otic compounds  [75, 76] . Within the SULT superfamily, 
10 distinct human SULT forms are known so far, differ-
ing in their tissue distribution and substrate specifici-
ties. The best described is the SULT1A family, consisting 
of SULT1A1, 1A2, and 1A3 in human tissue. Common 
functional polymorphisms of the transcribed region are 
known for many of them. In this respect, the most impor-
tant enzyme appears to be SULT1A1 which catalyzes the 
sulfonylation of 4-hydroxytamoxifen and endoxifen both 
active metabolites of tamoxifen  [77] . The gene encod-
ing SULT1A1 is mapped to the short arm of the chromo-
some 16p12.1-p11.2. The  SULT1A1∗2 variant was the most 
common of the two common non-synonymous SNPs 
observed, namely  SULT1A1∗2 (638G > A, Arg213His) and 
 SULT1A1∗3 (667A > G, Met223Val). Individuals carrying 
the variant allele  SULT1A1∗2 have a diminished capac-
ity to sulfate the substrates of SULT1A1 due to shorter 
protein life. Lower enzyme activity for SULT1A1 induced 
by  SULT1A1∗2 may theoretically lead to longer exposure 
of tamoxifen ’ s active metabolites and thereby a favorable 
clinical outcome  [78] . 
 The frequency of  SULT1A1∗2 in Italian populations was 
established in two studies aimed to investigate the correla-
tion between polymorphisms in metabolic genes such as 
 SULT1A1 with the risk of gastric cancer  [51] or the efficacy 
of tamoxifen to prevent the breast cancer  [56] . In the study 
by Boccia et  al.  [51] , among 254 control subjects, 61.4% 
showed a homozygous  SULT1A1∗1/∗1 genotype, 33.5% a 
heterozygous  SULT1A1∗1/∗2 genotype, and 5.1% a homozy-
gous  SULT1A1∗2/∗2 genotype with a  SULT1A1 ∗2 allele fre-
quency of 0.22. In the study by Serrano et al.  [56] , among 
136 subjects, 52.2% showed a homozygous  SULT1A1∗1/∗1 
genotype, 40.4% a heterozygous  SULT1A1∗1/∗2 geno-
type, and 7.4% a homozygous  SULT1A1∗2/∗2 genotype 
with a  SULT1A1 ∗2 allele frequency of 0.28 (Table 4). The 
 SULT1A1∗2 allele frequency observed in Italian subjects 
was quite similar to that reported in Caucasian popula-
tions ranging from 0.25 to 0.36  [79] . 
 Finally, gene duplication and deletion was also more 
common in the  SULT1A1 gene, and a correlation between 
the enzymatic activity and  SULT1A1 gene copy numbers 
has been observed  [80] . In the same study, the authors 
reported that 5% of Caucasian subjects contained a single 
copy of the gene and 26% had three or more copies, while 
63% of African American subjects had three or more 
copies  [80] . To date, no data about gene duplication and 
deletion have been reported in Italian populations. 
 Glutathione S-transferases 
 Currently at least seven cytosolic glutathione S-trans-
ferase (GST) families have been identified in human being 
 –  α (A),  μ (M),  θ (T),  π (P),  σ (S),  ω (O), and  ζ (Z)  – based 
on sequence and immunochemical relatedness and sub-
strate specificity  [81, 82] . They play a significant role in the 
detoxification of reactive and toxic electrophiles such as 
reactive oxygen species (superoxide radical and hydrogen 
peroxide) that arise through normal metabolic processes. 
 All the human GSTs are highly polymorphic, but the 
impact of GSTs and their variants on drug therapy has not 
been studied in detail. However, it is emerging that GSTs 
may contribute to anticancer drug resistance as they facil-
itate the removal of drugs from cells  [83] . In fact, several 
anticancer drugs including etoposide, doxorubicin, cis-
platin, oxaliplatin, and carboplatin are GST substrates. 
Several types of allelic variants have been identified in the 
 GST gene families, and the most investigated are  GSTM1 
and  GSTT1 deletions, which result in the null activity of 
their respective enzymes, and the  GSTP1 SNPs, leading 
to alterations in the substrate binding site and enzyme 
activity. Two sites in the DNA sequence are characterized 
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by an A > G transition at nucleotide 313 (point mutation 
in exon 5) and a C > T transition at nucleotide 341 (point 
mutation in exon 6). The resulting codon variants encode 
for the amino acids Ile105 or Val105 and Ala114 or Val114 
at the electrophilic  “ H ” -site level. Four alleles have been 
described at the GSTP1 locus located on chromosome 
11q13:  GSTP1∗A (wild-type Ile105 → Ala114),  GSTP1∗B 
(Val105 → Ala114),  GSTP1∗C (Val105 → Val114), and 
 GSTP1∗D (Ile105 → Val114)  [84, 85] . Individuals carrying at 
least one copy of the variant  GSTP1∗B show a greater risk 
of disease from cytotoxic drugs such as alkylating agents, 
topoisomerase inhibitors, antimetabolites, and tubulin 
inhibitors  [86] . This finding suggests that  GSTP1∗A is cyto-
protective against the toxic effects of chemotherapy and 
that toxicity is greater in carriers of variant alleles that 
are functionally less competent. However, there have also 
been reports that GSTP1 variants may be associated with 
more favorable outcomes with certain chemotherapeutic 
agents, such as cyclophosphamide, adriamycin, and oxali-
platin  [87] , and there was a decreased risk of developing 
the cumulative neuropathy that is a major dose-limiting 
toxicity of treatment with oxaliplatin  [88] . Furthermore, 
the conversion of azathioprine from its pro-drug form to 
the active metabolite mercaptopurine, an immunosup-
pressive compound, may be impaired in carriers of null 
alleles of GSTM1 reducing the production of azathioprine 
active metabolites  [89] . Therefore, the pharmacogenet-
ics of GSTP1 and GSTM1 may be useful in the prediction 
of response to such drugs, even though these findings 
should be confirmed by a larger number of patients in 
ongoing clinical studies. 
 In a study from a large sample of an Italian popula-
tion, the frequencies of  GSTM1 and  GSTT1 null genotype 
were found to be 49.2% and 28.3%, respectively  [57] . In 
another study involving a population from central Italy, 
the frequencies were found to be 50.4% and 16.7%, respec-
tively (Table 3)  [58] . The frequencies of the GSTM1 and 
GSTT1 null phenotypes in Italian population  [57, 58] are in 
line with those observed in Caucasian populations, 40% –
 65% and 10% – 40%, respectively  [57, 90] . 
 The  GSTP1∗A ,  GSTP1∗B ,  GSTP1∗C , and  GSTP1∗D allelic 
frequencies observed in an Italian population, mainly 
from the region Lazio, were the following:  f (A) = 0.71, 
 f (B) = 0.24,  f (C) = 0.05 and  f (D) = 0 with a genotype frequency 
of  GSTP1 ∗A/∗A ,  GSTP1 ∗A/∗B ,  GSTP1 ∗A/∗C ,  GSTP1 ∗B/∗B , 
and  GSTP1 ∗B/∗C genotype of 51.2%, 31.6%, 8.0%, 6.4%, 
and 2.8%, respectively (Table 3)  [59] . Moreover, in a study 
aimed to investigate the possible association between 
GSTP1 polymorphisms with the risk of breast cancer, the 
authors only investigated the 313A > G non-synonymous 
polymorphism in exon 5 (Ile105Val) in 544 Italian women 
healthy volunteers. In this study, the GSTP1 frequency of 
genotypes Ile/Ile, Ile/Val, and Val/Val was found to be 
23.5%, 62.5% and 14.0%, respectively (Table 4)  [60] . To 
the best of our knowledge, the frequency of the  GSTP1∗A , 
 GSTP1∗B ,  GSTP1∗C , and  GSTP1∗D genotypes has not been 
investigated in other Caucasian populations. 
 Conclusions 
 Marked differences have been shown in the distribution of 
allelic variants affecting the activity of drug-metabolizing 
enzymes in different populations. It is therefore of great 
clinical significance to define the genetic profile of dif-
ferent populations between and within ethnic groups. In 
order to characterize the Italian population, available data 
from different studies have been collected. In general, the 
frequency of polymorphisms in the CYP genes as well as in 
the investigated phase II enzymes in the Italian population 
was similar to values reported for other Caucasian popula-
tions. However, the prevalence of  CYP2D6 gene duplica-
tion among Italians was found to be very high, confirming 
the higher frequency of  CYP2D6 UMs in the Mediterranean 
area compared to Northern Europe. It is worth noting that 
a geographic gradient in the FMO3 polymorphism dis-
tribution was also seen, the Italian population showing 
higher similarity to other Mediterranean populations than 
to North Europeans. 
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